Key result
The combined AG+GG genotype of the MTRR A66G polymorphism was associated with a significantly elevated risk of congenital heart diseases (OR 1.6) compared to healthy controls.
Why the study?
Are MTRR A66G and MTHFR C677T gene polymorphisms associated with congenital heart diseases in an Iranian population?
Case-Control (n=300)
No
Are MTRR A66G and MTHFR C677T gene polymorphisms associated with congenital heart diseases in an Iranian population?
Odds Ratio: 1.6 (95% CI 1–2.6)
Absolute Event Rate: 69.9% vs 58.5%
p-value: p=0.03
The C677T polymorphism of the MTHFR gene is significantly associated with VSD, and the A66G polymorphism of the MTRR gene may contribute to the development of TOF in the Iranian population.
May support MTRR A66G as CHD risk marker in Iranians; hypothesis-generating and requires validation before any screening role.
BACKGROUND: The 5, 10-methyleneterahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) are two essential enzymes involved in folate metabolism. The relationship between genetic polymorphisms and congenital heart defects (CHDs) is inconsistent. Our aim was to investigate the association between two well-known polymorphisms of MTHFR and MTRR genes, C677T and A66G, respectively, and CHDs in Iranian patients. METHODS: We enrolled 74 patients with ventricular septal defect (VSD) and 79 with tetralogy of fallot (TOF) along with 147 healthy controls. C677T and A66G polymorphisms were detected using tetra-primer ARMS (amplification refractory mutation system) PCR. RESULTS: Individuals carrying homozygote mutant (TT) genotype of C677T polymorphism represented the highest risk for CHDs (OR=7.3, 95% CI: 0.8-61, P=0.06). Also, significantly increased risk of VSD was observed in individuals with TT genotype (OR=10, 95% CI: 1-92.2, P=0.04). However, the frequency for variant allele (T) of C677T polymorphism was not statistically different between cases and controls (16.3% and 20.9%, respectively). For A66G polymorphism, we found that AG and GG genotypes had higher frequencies in the patients (48.4% and 21.6% respectively) than controls (42.9% and 15.6%, respectively). In line with this, combined AG+GG genotype represented with significantly elevated risk of CHDs (OR=1.6; 95% CI: 1-2.6, P=0.03). AG+GG combination was also identified as a risk factor for TOF (OR=1.8, 95% CI: 1-3.3, P=0.04). CONCLUSION: We demonstrated that C677T polymorphism of MTHFR gene was significantly associated with VSD in our patients. Our study also suggested that A66G polymorphism of MTRR gene may contribute to the development of TOF in Iranians.
No takes yet. Share an insight, caveat, or question.
Noori et al. (2017) conducted a case-control in Congenital heart diseases (Ventricular septal defect and Tetralogy of Fallot) (n=300). MTRR A66G and MTHFR C677T polymorphisms vs. Wild-type genotypes / Healthy controls was evaluated on Risk of congenital heart diseases associated with MTRR A66G combined AG+GG genotype (OR 1.6, 95% CI 1-2.6, p=0.03). The combined AG+GG genotype of the MTRR A66G polymorphism was associated with a significantly elevated risk of congenital heart diseases (OR 1.6) compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: